DNAVision to offer Ipsogen's gene profiling tests for breast cancer:
This article was originally published in Clinica
Marseille, France-based Ipsogen has secured a contract to supply DNAVision, a Belgium-based provider of pharmacogenomic testing services, with gene profiling tests for breast cancer. The agreement will see Ipsogen's tests being offered to institutions and patients in a CLIA/ISO17025 certified environment, "at the level of quality of quantitative PCR, the industry standard," said Ipsogen. The agreement comes shortly after the company gained a licence to Affymetrix' microarray technology, which is incorporated in Ipsogen's molecular diagnostic products.
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.